Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Total Liabilities (2016 - 2025)

Alterity Therapeutics has reported Total Liabilities over the past 5 years, most recently at $2.4 million for Q2 2019.

  • For Q2 2019, Total Liabilities rose 17.38% year-over-year to $2.4 million; the TTM value through Jun 2019 reached $2.4 million, up 17.38%, while the annual FY2019 figure was $2.4 million, 17.38% up from the prior year.
  • Total Liabilities for Q2 2019 was $2.4 million at Alterity Therapeutics, down from $877.0 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $2.1 billion in Q2 2015 and troughed at $1.2 million in Q2 2017.
  • A 5-year average of $529.3 million and a median of $2.1 million in 2016 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: crashed 99.93% in 2017 and later soared 62712.29% in 2018.
  • Year by year, Total Liabilities stood at $1.7 million in 2015, then rose by 26.36% to $2.1 million in 2016, then tumbled by 34.69% to $1.4 million in 2017, then soared by 62712.29% to $877.0 million in 2018, then plummeted by 99.73% to $2.4 million in 2019.
  • Business Quant data shows Total Liabilities for ATHE at $2.4 million in Q2 2019, $877.0 million in Q4 2018, and $2.0 million in Q2 2018.